Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts

Urothelial Carcinoma of the Bladder Clinical Trial

Official title:
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts

Status Completed

Clinical Trial Summary

Purposes are to determine whether various cohorts of bladder cancer patients have detectable tCTC's, determine it tCTC levels vary with the natural history of bladder cancer and to see if tCTC's provide novel information.Study population are various cohorts of patients diangosed with urothelial carcinoma of the bladder.Procedures include a venous blood draw, up to two times, over a 6 month period for collection of tCTC's. Up to 15 mL's of blood will be collected at each blood draw.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Neoplastic Cells, Circulating
Urinary Bladder Neoplasms
Urothelial Carcinoma of the Bladder

Clinical Trial Details

NCT number	NCT02246738
Study type	Observational
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase
Start date	August 2014
Completion date	October 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01520038` - Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT02710734` - Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)	Phase 2
Active, not recruiting	`NCT04432857` - AN0025 and Pembrolizumab Combination in Advanced Solid Tumors	Phase 1